Sheller, P.C. law firm Risperdal cases continue, with trials beginning October, 2015. From the daily newspaper The Legal Intelligencer: “A second wave of trials in the Risperdal mass tort has been scheduled for
Stephen Sheller was quoted in a July 31, 2015 article discussing Risperdal research that was “manipulated by a drug company and understated the risks of a powerful antipsychotic used to treat kids with behavioural
Reports suggest that the Bair Hugger Forced Air Warming system, which is used in operating rooms across the country, can increase patients’ risk of developing MRSA, sepsis, and other serious infections. Sheller, P.C.
Long term data about the Essure contraceptive device suggest that it may pose risks of serious complications. Essure is a birth control device that consists of two metal coils placed inside the fallopian tubes to
Sheller, P.C. attorneys are investigating the newer class of diabetes drugs following FDA warnings. ABOUT THE DRUGS Invokana (Invokamet) is a relatively new SGLT2 inhibitor diabetes drug that is intended to be used
Risperdal Accords Don’t Mean Swift End to Litigation by P.J. D’Annunzio, The Legal Intelligencer After settlement of the third case to head to the courtroom in Philadelphia’s Risperdal mass tort, the lead trial attorney
Stephen Sheller was honored with a Lifetime Achievement Award Wednesday, May 20 2015 from American Lawyer Media’s daily newspaper, The Legal Intelligencer. The award was based on his record of verdicts and settlements, service
The attorneys at Sheller P.C. have been recognized again this year as SuperLawyers. For the twelfth consecutive year, founder Stephen A. Sheller has been selected by the organization and specifically honored as one of the Top